论文部分内容阅读
他汀类药物治疗降低低密度脂蛋白胆固醇(LDL-C),可降低无肾病患者的心肌梗死(MI)、缺血性卒中危险,并减少其冠状动脉血运重建的需要。对于eGFR高于60 ml.min-1.1.73 m-2的的慢性肾病患者来说,心血管病的病因常常由于动脉粥样硬化所致,他汀类药物治疗带来的益处独立于肾功能。但当eGFR低于30 ml.min-1.1.73 m-2时,肾病患者合并其他的心血管病理生理变化,例如血管硬化、钙化,心脏
Statin treatment reduces LDL-C, reduces the risk of myocardial infarction (MI), ischemic stroke, and the need for revascularization in patients without nephropathy. Cardiovascular disease is often due to atherosclerosis in chronic kidney disease patients with eGFR greater than 60 ml.min-1.1.73 m-2, and the benefits of statin therapy are independent of renal function. However, when eGFR is less than 30 ml.min-1.1.73 m-2, nephropathy patients have other cardiovascular pathophysiological changes such as vascular sclerosis, calcification, heart